Protection of the human gut microbiome from antibiotics
J De Gunzburg, A Ghozlane, A Ducher… - The Journal of …, 2018 - academic.oup.com
The Journal of infectious diseases, 2018•academic.oup.com
Background Antibiotics are life-saving drugs but severely affect the gut microbiome with
short-term consequences including diarrhea and selection of antibiotic-resistant bacteria.
Long-term links to allergy and obesity are also suggested. We devised a product, DAV132,
and previously showed its ability to deliver a powerful adsorbent, activated charcoal, in the
late ileum of human volunteers. Methods We performed a randomized controlled trial in 28
human volunteers treated with a 5-day clinical regimen of the fluoroquinolone antibiotic …
short-term consequences including diarrhea and selection of antibiotic-resistant bacteria.
Long-term links to allergy and obesity are also suggested. We devised a product, DAV132,
and previously showed its ability to deliver a powerful adsorbent, activated charcoal, in the
late ileum of human volunteers. Methods We performed a randomized controlled trial in 28
human volunteers treated with a 5-day clinical regimen of the fluoroquinolone antibiotic …
Background
Antibiotics are life-saving drugs but severely affect the gut microbiome with short-term consequences including diarrhea and selection of antibiotic-resistant bacteria. Long-term links to allergy and obesity are also suggested. We devised a product, DAV132, and previously showed its ability to deliver a powerful adsorbent, activated charcoal, in the late ileum of human volunteers.
Methods
We performed a randomized controlled trial in 28 human volunteers treated with a 5-day clinical regimen of the fluoroquinolone antibiotic moxifloxacin in 2 parallel groups, with or without DAV132 coadministration. Two control goups of 8 volunteers each receiving DAV132 alone, or a nonactive substitute, were added.
Results
The coadministration of DAV132 decreased free moxifloxacin fecal concentrations by 99%, while plasmatic levels were unaffected. Shotgun quantitative metagenomics showed that the richness and composition of the intestinal microbiota were largely preserved in subjects co-treated with DAV132 in addition to moxifloxacin. No adverse effect was observed. In addition, DAV132 efficiently adsorbed a wide range of clinically relevant antibiotics ex vivo.
Conclusions
DAV132 was highly effective to protect the gut microbiome of moxifloxacin-treated healthy volunteers and may constitute a clinical breakthrough by preventing adverse health consequences of a wide range of antibiotic treatments.
Clinical Trials Registration
NCT02176005.
Oxford University Press